

Ozempic is a prescription-only once-weekly GLP-1 injection containing semaglutide, used for type 2 diabetes and increasingly for doctor-supervised weight management in Singapore. It works by mimicking the GLP-1 hormone, which helps regulate appetite, increase fullness, slow digestion, and reduce calorie intake, leading to gradual and sustained weight loss when combined with lifestyle changes.
The treatment is typically started at a low “starter dose” (0.25 mg weekly) and gradually increased to 0.5 mg and then 1 mg weekly depending on tolerance and clinical response.



The monthly cost of treatment varies based on several factors:
This means the cost may be lower in the early stages and stabilises once the patient reaches their maintenance dose.
This treatment is often considered for:
Certain patients are not suitable for semaglutide 0.25–1mg weekly injections, including:
















